<DOC>
	<DOC>NCT02994745</DOC>
	<brief_summary>The purpose of this study is to evaluate the Pharmacokinetics and Safety / Tolerability of Fimasartan and Atorvastatin in Healthy Male volunteers.</brief_summary>
	<brief_title>A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Atorvastatin in Healthy Male Volunteers.</brief_title>
	<detailed_description>This is a randomized, open-label, single dose, 3x3 partial replicated crossover study to evaluate the pharmacokinetics and safety/tolerability. Within each period, randomized subjects will be 2 dosing regimens with a fixed dose combination of Fimasartan/Atorvastatin and co-administration of Fimasartan and Atorvastatin.</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>A Healthy male aged 1950 years Body weight is over 55kg and BMI 18 ~ 27(kg/m2). A subject provide written informed consent which he voluntarily confirms willingness to participate in a study, having been informed of the full details of the study and comply with the protocol. A subject who is eligible according to investigator's assessment History or presence of clinically significant medical or psychiatric condition or disease. History of gastrointestinal disease and resection Hypersensitivity to ingredient of investigational product(IP) and other medication, food. Genetic Problem such as Galactose intolerance, Lapp lactase deficiency or Glucosegalactose malabsorption. A subject who take a drug that inhibit or induce significantly DrugMetabolizing Enzyme within 1months. Positive results for serum examination(HIV, B and C viral test, Syphilis). Seated BP is less than 100/65 mmHg or greater than 140/90 mmHg at screening. Participation in any other study within 3months. History of whole blood donation within 2months and Apheresis 2 weeks.</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>